[go: up one dir, main page]

MX2017015279A - Exasomas y su uso como vacunas. - Google Patents

Exasomas y su uso como vacunas.

Info

Publication number
MX2017015279A
MX2017015279A MX2017015279A MX2017015279A MX2017015279A MX 2017015279 A MX2017015279 A MX 2017015279A MX 2017015279 A MX2017015279 A MX 2017015279A MX 2017015279 A MX2017015279 A MX 2017015279A MX 2017015279 A MX2017015279 A MX 2017015279A
Authority
MX
Mexico
Prior art keywords
exosomes
vaccine
pathogen
animal
provides
Prior art date
Application number
MX2017015279A
Other languages
English (en)
Inventor
Antonio Del Portillo Obando Hernando
Enrique BORRÁS SERRES Francisco
José FRAILE SAUCE Lorenzo
Roberto Montaner Tarbes Sergio
MONTOYA GONZÁLEZ Maria
Original Assignee
Innovex Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovex Therapeutics S L filed Critical Innovex Therapeutics S L
Publication of MX2017015279A publication Critical patent/MX2017015279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona exasomas aislados de un animal donde el animal (a) ha superado una enfermedad causada por un patógeno, y (b) está libre del patógeno causante de la enfermedad. La invención también proporciona procedimientos de obtención de estos exasomas y el uso de los mismo en terapia.
MX2017015279A 2015-06-03 2016-06-03 Exasomas y su uso como vacunas. MX2017015279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201530775 2015-06-03
PCT/EP2016/062637 WO2016193422A1 (en) 2015-06-03 2016-06-03 Exosomes and their use as vaccine

Publications (1)

Publication Number Publication Date
MX2017015279A true MX2017015279A (es) 2018-05-15

Family

ID=56119476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015279A MX2017015279A (es) 2015-06-03 2016-06-03 Exasomas y su uso como vacunas.

Country Status (6)

Country Link
US (1) US11020471B2 (es)
EP (1) EP3302535A1 (es)
CA (1) CA2992639A1 (es)
MX (1) MX2017015279A (es)
RU (1) RU2763524C2 (es)
WO (1) WO2016193422A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302535A1 (en) * 2015-06-03 2018-04-11 Innovex Therapeutics, S.L. Exosomes and their use as vaccine
CA3107687A1 (en) * 2018-02-26 2019-08-29 Claudia Zylberberg Immune cell activation
US12296023B2 (en) 2018-08-16 2025-05-13 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
WO2020060479A1 (en) * 2018-09-21 2020-03-26 City University Of Hong Kong Cargo loaded extracellular vesicles
JP2025063000A (ja) * 2023-10-03 2025-04-15 緑茵生技股▲ふん▼有限公司 ポリペプチド及びそれを血糖のコントロール及び／又は脂肪を減少するのに用いる用途
CN117771348B (zh) * 2023-11-27 2024-09-03 山东省农业科学院畜牧兽医研究所 猪髋动脉内皮细胞源性外泌体在制备细菌疫苗中的应用
BE1032025B1 (de) * 2023-11-27 2025-04-30 Inst Animal Science & Veterinary Medicine Shandong Aas Anwendung eines aus endothelzellen der schweine-hüftarterien gewonnenen exosoms bei der herstellung eines bakteriellen impfstoffs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2785543B1 (fr) * 1998-11-05 2003-02-28 Inst Nat Sante Rech Med Exosomes modifies et utilisations
EP3302535A1 (en) * 2015-06-03 2018-04-11 Innovex Therapeutics, S.L. Exosomes and their use as vaccine

Also Published As

Publication number Publication date
WO2016193422A1 (en) 2016-12-08
RU2763524C2 (ru) 2021-12-30
RU2017146398A (ru) 2019-07-10
CA2992639A1 (en) 2016-12-08
RU2017146398A3 (es) 2019-11-05
US20180161416A1 (en) 2018-06-14
US11020471B2 (en) 2021-06-01
EP3302535A1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
ZA202004557B (en) Modulatory polynucleotides
MX2017015279A (es) Exasomas y su uso como vacunas.
MX2022007522A (es) Anticuerpos anti-cd27.
WO2017030823A3 (en) Anti-tigit antibodies
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
PH12018500578A1 (en) Methods of treating inflammatory diseases
TW201613901A (en) New compounds
GB2541571A (en) Pharmaceutical compositions
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12016501841A1 (en) Immunosuppressant formulation
MY191539A (en) Streptococcal vaccine
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
ZA201704596B (en) Foot-and-mouth disease vaccine
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12017500602A1 (en) Methods for treating ocular conditions
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
UA96409U (uk) Спосіб реабілітації жінок після перенесеного сальпінгоофориту